Funding for this research was provided by:
National Institutes of Health (NS090934, AG04867801, S10OD020129)
Received: 26 November 2018
Accepted: 20 February 2019
First Online: 27 February 2019
Ethics approval and consent to participate
: Animal husbandry, housing and all procedures were performed following protocols approved by the Animal Studies Committee and Washington University School of Medicine.
: Not applicable.
: DMH is listed as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. DMH co-founded and is on the scientific advisory board of C2N Diagnostics, LLC. C2N Diagnostics, LLC has licensed certain anti-tau antibodies to AbbVie for therapeutic development. DMH is on the scientific advisory board of Proclara and Denali and consults for Genentech and AbbVie.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.